Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphamine.
The increased food intake in the rat during the first two hours of the dark cycle was significantly inhibited by central pretreatment with either the selective kappa opioid antagonist, nor-binaltorphamine (NorBNI, 20 micrograms, i.c.v., 53-54%) or naltrexone (NTX, 20 micrograms, i.c.v., 47-60%). Short-term (2 h) intake of a high-fat diet was significantly inhibited by central NorBNI (1-20 micrograms, 33-79%) and NTX (20 micrograms, 47-51%). Hyperphagia induced by the anti-metabolic glucose analogue, 2-deoxy-D-glucose was significantly inhibited by central NorBNI (20 micrograms, 40-68%) and NTX (20 micrograms, 28-69%). These data suggest that the kappa receptor subtype, in addition to other opioid receptor subtypes, influence these forms of feeding behavior.
Arjune
D
D
Department of Psychology and Neuropsychology, Doctoral Sub-Program, Queens College, City University of New York, Flushing 11367.
Bodnar
R J
RJ
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D002940:Circadian Rhythm; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects* / Q000502:physiology; D017473:Receptors, Opioid, kappa; D012016:Reference Values
D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone